한글목차

비만 시장에 대해 조사했으며, 출시 약제와 후기 개발 단계에 있는 파이프라인 의약품제 양쪽 모두에 초점을 맞추어 중등도-중증 비만에 대한 현재 치료법과 새로운 치료법에 대해 분석했습니다.

답변을 얻을 수 있는 주요 질문

• Wegovy, Zepbound/Mounjaro, Saxenda, Contrave/Mysimba와 같은 현재 비만 치료제는 임상으로 어떻게 사용되고 있는가?
• 최근 출시된 비만 치료법 중에서 가장 유망한 작용기전과 제품은?
• 현재 치료 상황에 가장 큰 영향을 미치는이라고 예측되는 비만용 파이프라인 의약품은?
• 비만 치료 향후 처방 동향으로 영향을 미치는 가능성이 가장 높은 진행중 또는 향후 임상시험은?
• 비만 치료에 가장 큰 가능성을 나타내는 초기 단계 후보의약품은?
• 중등도로부터 중증 비만에 대한 전체적인 치료 알고리즘은 향후 어떻게 진화해 나갈 것으로 예측되는가?

주요 브랜드

영문목차

This report provides a detailed analysis of current and emerging therapies for moderate-to-severe obesity, focusing on both marketed and late-stage pipeline agents. Drawing on interviews with leading KOLs from North America and Europe, it explores which therapies are most likely to expand or shift the market, the role of oral versus injectable approaches in driving adoption, and how differentiation on efficacy, safety, and comorbidity management could influence prescribing and payer decisions. The findings shed light on where competitive pressures are emerging, which late-stage trials may alter positioning among leading players, and how long-term management strategies are expected to shape future treatment pathways.

Key Questions Answered:

• How are current obesity drugs like Wegovy, Zepbound/Mounjaro, Saxenda, and Contrave/Mysimba being used in clinical practice?
• What are the most promising mechanisms of action and products among recently launched obesity therapies?
• Which pipeline drugs for obesity are expected to have the greatest impact on the current treatment landscape?
• Which ongoing or upcoming clinical trials are most likely to influence future prescribing trends in obesity management?
• Which early-stage drug candidates show the most potential for treating obesity?
• How is the overall treatment algorithm for moderate-to-severe obesity expected to evolve in the coming years?

Key Brands:

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.